Mallinckrodt begins enrolment for Phase IV study of HP Acthar Gel to treat SLE

Irish biopharmaceutical company Mallinckrodt has begun enrolment for its Phase IV clinical study of HP Acthar Gel to treat systemic lupus erythematosus (SLE) patients with persistently active disease.

Source: Drug Development Technology - November 16, 2016 Category: Pharmaceuticals Source Type: news